Shots:

• Arrakis to receive $190M up front in cash and is eligible to get several billion dollars in pre/clinical and commercial milestones along with royalties for products emerging from the collaboration
• Arrakis will be responsible for discovery and research activities of each target to a defined point while Roche will get right to exclusively pursue further pre/ clinical development
• The collaboration will leverage Roche’s rSM discovery platform to discover novel therapies targeting all Roche’s research and development areas

Click here ­to­ read full press release/ article 

 Ref: Businesswire | Image: Roche